Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials

Data from included trials suggests benefit of bone-targeted agents in lung cancer for the prevention of SREs and bone pain. There is a trend toward improvement in overall survival and progression-free survival, although further research is needed. Impact on quality of life and key subgroups for benefit both require future research.